Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]
Not Applicable
Terminated
- Conditions
- Type 2 Diabetes Treated With Insulin
- Interventions
- Device: Livongo-Insulia Study App
- Registration Number
- NCT03980236
- Lead Sponsor
- Livongo Health
- Brief Summary
The Livongo-Insulia Study App Pilot Study (LISA Pilot) is a 3-month, prospective, interventional study. The purpose of this pilot study is to evaluate the feasibility of using the Livongo-Insulia Study App for individuals with type 2 diabetes using basal insulin. This will be assessed by measuring the impact of the Livongo-Insulia Study App on glycemic control for these individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- Age ≥ 18 years
- Lives in the U.S.
- Able to speak, read and write in English
- Diagnosed with type 2 diabetes
- Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo, Basaglar, Tresiba U-100) and taking 1 injection per day
- Takes a daily dose ≤ 0.75 units/kg
- Estimated A1c ≥ 8% (based on existing Livongo data)
- Has been enrolled in Livongo for at least 12 weeks
- Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS 8 or newer)
- Willing to complete study questionnaires
- Willing to complete at-home A1c kits
- Willing to check before breakfast blood glucose at least once per day
Exclusion Criteria
- Diagnosis of type 1 diabetes
- Currently using a long-acting basal insulin analog that is not supported by Insulia
- Currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins
- Currently pregnant or planning pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Livongo-Insulia Study App Arm Livongo-Insulia Study App Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
- Primary Outcome Measures
Name Time Method Change in A1c 12 weeks Change in A1c from baseline to 12 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Livongo
🇺🇸Mountain View, California, United States